Get the Stockscreener App
17.89
1.94%
0.34
After Hours:
17.89
Arvinas Inc stock is traded at $17.89, with a volume of 714.66K.
It is up +1.94% in the last 24 hours and down -5.84% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$17.55
Open:
$17.95
24h Volume:
714.66K
Relative Volume:
0.88
Market Cap:
$1.23B
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-3.8308
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
-0.61%
1M Performance:
-5.84%
6M Performance:
-33.96%
1Y Performance:
-54.67%
1-Day Range:
$17.65
$18.30
1-Week Range:
$17.46
$19.30
52-Week Range:
$17.08
$53.08
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
17.89 | 1.23B | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Citadel Advisors LLC's Strategic Acquisition of Arvinas Inc. Sha - GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - PR Newswire
When the Price of (ARVN) Talks, People Listen - Stock Traders Daily
The Escalator: Merck, Novartis, Arvinas and more - MM+M Online
Brokers Set Expectations for Arvinas FY2025 Earnings - MarketBeat
Arvinas terminates lease agreement, frees up future liabilities - Investing.com India
Arvinas terminates lease agreement, frees up future liabilities By Investing.com - Investing.com Australia
Arvinas Holding Company Adjusts Real Estate Strategy - TipRanks
Assenagon Asset Management S.A. Buys 777 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas looks for new chief commercial officer - The Pharma Letter
Arvinas Repeat Insider Selling Not A Positive Indicator - Simply Wall St
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 - The Motley Fool
Arvinas, Inc. (NASDAQ:ARVN) Receives $63.50 Average PT from Analysts - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains? - MSN
Arvinas (NASDAQ:ARVN) Sets New 12-Month LowShould You Sell? - MarketBeat
Arvinas stock touches 52-week low at $17.35 amid market challenges - Investing.com Australia
Arvinas outlines 2025 clinical trial plans for breast cancer drug By Investing.com - Investing.com Australia
Arvinas Announces Updates on Clinical Trials Progress - TipRanks
Arvinas outlines 2025 clinical trial plans for breast cancer drug - Investing.com India
Arvinas Updates Guidance for First- and Second-Line Phase 3 - GlobeNewswire
Arvinas Plans Two Phase 3 Trials for Breakthrough Breast Cancer Drug, Expands Pipeline for 2025 - StockTitan
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update - Business Upturn
Metastatic Prostate Cancer Market to Expand Significantly by 2034, States DelveInsight Report | Merck, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion Corporation - Barchart
Metastatic Prostate Cancer Market to Expand Significantly - openPR
JPMorgan Chase & Co. Grows Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
JPMorgan Chase & Co. Increases Position in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas (NASDAQ:ARVN) Trading 9.2% HigherHere's Why - MarketBeat
How To Trade (ARVN) - Stock Traders Daily
March 21st Options Now Available For Arvinas (ARVN) - Nasdaq
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Increases By 6.5% - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Sees Significant Increase in Short Interest - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Receives $63.50 Consensus Target Price from Brokerages - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Arvinas (NASDAQ:ARVN) Shares Down 3.3%Should You Sell? - MarketBeat
Arvinas' Vepdegestrant: Why The Data May Not Hold Up (NASDAQ:ARVN) - Seeking Alpha
Barclays PLC Purchases 80,984 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Long Term Trading Analysis for (ARVN) - Stock Traders Daily
Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by State Street Corp - MarketBeat
Arvinas (NASDAQ:ARVN) Trading Down 6.2%Time to Sell? - MarketBeat
New Haven-based Arvinas to expand Science Park footprint; renews leases - Hartford Business Journal
New Haven-based Arvinas to expand Science Park footprint; extends leases - Hartford Business Journal
Arvinas's SWOT analysis: biotech firm's stock faces pivotal trial results By Investing.com - Investing.com Australia
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):